Isolation and characterization of tumorigenic extrahepatic cholangiocarcinoma cells with stem cell‐like properties

Wang, Min; Shen, Min; Yu, Yang; Tian, Rui; Zhu, Feng; Jiang, Jianxin; Du, Zhifeng; Hu, Jun; Liu, Wensong; Qin, Renyi

doi:10.1002/ijc.25317

Cited by 51 publications

(58 citation statements)

References 33 publications

(79 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this respect, new exciting insights into tumor biology have been recently provided since the discovery of cancer stem cells (CSCs) in many human solid tumors including PLT [14][15][16]. CSCs are considered to be responsible for tumor growth, recurrence and metastases including differentiation of heterogeneous cell populations within tumors [17].…”

Section: Introductionmentioning

confidence: 99%

Methylation and liver cancer

Raggi

Invernizzi

2013

Clinics and Research in Hepatology and Gastroenterology

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Methylation and liver cancer

Raggi

Invernizzi

2013

Clinics and Research in Hepatology and Gastroenterology

View full text Add to dashboard Cite

“…Therefore, subsequent investigations into the CSC-specific effects of the pharmacological inhibition of CXCR4 are required. In line with this theory, CXCR4 is upregulated in the CD24 + subpopulation, and the expression of this surface molecule is associated with a poor clinical outcome (19) and has been suggested as a marker for putative CSCs in BTC (32).…”

mentioning

confidence: 76%

Cytotoxic effects of chemokine receptor 4 inhibition by AMD3100 in biliary tract cancer cells: Potential drug synergism with gemcitabine

Mayr

Neureiter

Pichler

et al. 2015

Molecular Medicine Reports

View full text Add to dashboard Cite

Abstract. Biliary tract cancer (BTC) remains one of the most life-threatening types of cancer due to the lack of efficient therapies. Advanced tumour stages at the point of diagnosis and high chemoresistance are two of the predominant reasons for a 5-year survival rate of only ~5%. The present study investigated the effect of the chemokine receptor 4 (CXCR4) inhibitor AMD3100 (Plerixafor), alone and in combination with standard gemcitabine chemotherapy, on the proliferation of BTC cells. The expression of CXCR4 was analysed by reverse transcription-quantitative polymerase chain reaction in eight heterogeneously differentiated BTC cell lines. The effects of treatment with the CXCR4 antagonist, AMD3100, on cell viability and anchorage-independent growth, and the possible synergistic cytotoxic effects of AMD3100 with standard chemotherapeutics were assessed. The expression of CXCR4 was observed to a variable extent in all eight BTC cell lines, with SkChA-1 cells exhibiting the highest expression levels. Treatment with AMD3100 led to a marginal decrease in cell viability in the cell lines, with the exception of the CCSW-1 cells, and a significant reduction in the GBC, MzChA-1, SkChA.-1 and TFK-1 cell lines. The combined treatment of the SkChA-1 cells with varying concentrations of AMD3100 and standard gemcitabine chemotherapy revealed a more marked overall cytotoxicity, indicating a potential synergistic effect. In addition, AMD3100 significantly reduced anchorage-independent growth in the SkChA-1 cells. Overall, the results of the present study suggest that the inhibition of CXCR4 by AMD3100, in combination with gemcitabine, may be a suitable strategy for the future therapy of BTC.

show abstract

“…CD133 also is an important CSC marker in CCA [74]. CD133-positive cells showed higher invasiveness compared with CD133-negative cells.…”

Section: Csc Markers In Ccamentioning

confidence: 98%

Cancer Stem Cells and Aldehyde Dehydrogenase 1 in Liver Cancers

Tomita¹,

Kanayama²,

Niwa³

et al. 2017

Updates in Liver Cancer

View full text Add to dashboard Cite

The cancer stem cell (CSC) theory posits that a small population of cells with stem celllike features is responsible for tumor growth, resistance, and recurrence in many malignancies. This theory could be a useful paradigm for designing innovative targeted drug therapies. Liver cancer is the ifth most common cancer worldwide, with hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) as the predominant forms. Hepatic stem/progenitor cells are believed to be the origin of HCCs and CCAs; however, this remains a controversial topic. Aldehyde dehydrogenase (ALDH) is the main enzymatic system responsible for the clearance of acetaldehyde from the hepatocytes in the liver tissue. Therefore, ALDH1 has been suggested to be a potential, biological and CSC marker in liver cancers. We here provide an overview of the current state of knowledge of CSCs in liver and the role of ALDH1 in the development and progression of liver cancers and discuss its potential value as a prognostic and diagnostic biomarker.

show abstract

Isolation and characterization of tumorigenic extrahepatic cholangiocarcinoma cells with stem cell‐like properties

Cited by 51 publications

References 33 publications

Methylation and liver cancer

Methylation and liver cancer

Cytotoxic effects of chemokine receptor 4 inhibition by AMD3100 in biliary tract cancer cells: Potential drug synergism with gemcitabine

Cancer Stem Cells and Aldehyde Dehydrogenase 1 in Liver Cancers

Contact Info

Product

Resources

About